Scientists associated with Madras Diabetes Research Foundation (MDRF) find that it often presents with more severe beta-cell dysfunction and relatively less insulin resistance.
The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.
Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.
Doctors Without Borders says new class of drugs & insulin devices could be leading to ‘exorbitant corporate profiteering’. Study published in Journal of the American Medical Association.
Icodec has been touted as a therapy that could eliminate the need for daily or mealtime insulin injections for people with severe diabetes. It has not been approved by any country so far.
Danish pharmaceutical giant Novo Nordisk has said it is set to apply for regulatory approval of its once-a-week insulin drug, Icodec. Results of Phase-3 clinical trial shown 'promising results'.
UK patients may soon be covered for the device, which measures blood glucose, computes amount of insulin needed and then pumps that exact amount into bloodstream.
This special edition of Cut The Clutter, straight from the Siliguri corridor, details the strategic importance of the narrow strip of land in West Bengal, and how it’s a vital link connecting the Northeast to the rest of India.
We now live in a world order that will keep shifting. India must use this window. This also means we remain disciplined enough not to be knee-jerked into reacting to what Pakistan sees as its moment in the sun.
COMMENTS